Esperion Therapeutics Inc (ESPR) was Reiterated by Needham to “Buy” while Lowering the Price Target of the company shares to $ 25 from a previous price target of $77 . Needham advised their investors in a research report released on Jun 30, 2016.
Many Wall Street Analysts have commented on Esperion Therapeutics Inc. Shares were Downgraded by RBC Capital Mkts on Jun 29, 2016 to ” Sector Perform” and Lowered the Price Target to $ 15 from a previous price target of $30 .Esperion Therapeutics Inc was Downgraded by JP Morgan to ” Neutral” on Jun 29, 2016. Esperion Therapeutics Inc was Downgraded by Credit Suisse to ” Underperform” on Jun 29, 2016.
On the company’s financial health, Esperion Therapeutics Inc reported $-0.58 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Feb 25, 2016. Analyst had a consensus of $-0.64.During the same quarter in the previous year, the company posted $-0.49 EPS.
Esperion Therapeutics Inc closed down -6.52 points or -40.30% at $9.66 with 62,89,907 shares getting traded on Wednesday. Post opening the session at $10.5, the shares hit an intraday low of $9.58 and an intraday high of $11 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on May 5, 2016, Timothy M Mayleben (CEO) purchased 7,000 shares at $14.85 per share price. According to the SEC, on Mar 2, 2016, Gilbert S Omenn (director) purchased 5,000 shares at $15.28 per share price. On Apr 27, 2015, Dov A Md Goldstein (director) sold 217,469 shares at $107.73 per share price, according to the Form-4 filing with the securities and exchange commission.
Esperion Therapeutics Inc. is a pharmaceutical company focused on developing and commercializing oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of patients with hypercholesterolemia and other cardio-metabolic risk markers. The Company’s primary activities include conducting research and development activities including nonclinical preclinical and clinical testing performing business and financial planning recruiting personnel and raising capital. ETC-1002 the Company’s lead product candidate is an orally available once-daily small molecule designed to lower LDL-cholesterol levels and avoid the side effects associated with other LDL-cholesterol lowering therapies currently available. ETC-1002 is being developed for patients with hypercholesterolemia. One completed Phase IIb clinical study and a second that is nearing completion build upon a Phase I and Phase II clinical development program for ETC-1002.